PRME peer analysis
Prime Medicine (PRME) against its competitors: price, today's move, 1-year return and market value side by side.
PRME and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BEAM Beam Therapeutics | $27.00 | 4.37% | 13.46% | $2.88B |
| CRBU Caribou Biosciences | $0.44 | 7.71% | -81.00% | – |
| CRSP CRISPR Therapeutics | $49.35 | 1.63% | -14.36% | $5.02B |
| DSGN Design Therapeutics | $10.21 | 5.58% | 54.81% | – |
| EDIT Editas Medicine | $2.57 | 0.78% | -8.45% | $417.74M |
| MGX Metagenomi Therapeutics | $0.73 | -7.49% | -68.60% | – |
| NTLA Intellia | $11.39 | 2.60% | -9.84% | $1.72B |
| SCTX Scribe Therapeutics | $15.50 | 0.13% | – | – |
| PRME Prime Medicine | $4.65 | 4.49% | 2.79% | – |
- PRME's peers: BEAM (Beam Therapeutics), CRBU (Caribou Biosciences), CRSP (CRISPR Therapeutics), DSGN (Design Therapeutics), EDIT (Editas Medicine), MGX (Metagenomi Therapeutics), NTLA (Intellia), SCTX (Scribe Therapeutics).
Updated 2026-11-07 11:53 UTC